Literature DB >> 11533183

Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

C Leder1, J A Kleinschmidt, C Wiethe, M Müller.   

Abstract

Expression of the structural proteins L1 and L2 of the human papillomaviruses (HPV) is tightly regulated. As a consequence, attempts to express these prime-candidate genes for prophylactic vaccination against papillomavirus-associated diseases in mammalian cells by means of simple DNA transfections result in insufficient production of the viral antigens. Similarly, in vivo DNA vaccination using HPV L1 or L2 expression constructs produces only weak immune responses. In this study we demonstrate that transient expression of the HPV type 16 L1 and L2 proteins can be highly improved by changing the RNA coding sequence, resulting in the accumulation of significant amounts of virus-like particles in the nuclei of transfected cells. Data presented indicate that, in the case of L1, adaptation for codon usage accounts for the vast majority of the improvement in protein expression, whereas translation-independent posttranscriptional events contribute only to a minor degree. Finally, the adapted L1 genes demonstrate strongly increased immunogenicity in vivo compared to that of unmodified L1 genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533183      PMCID: PMC114488          DOI: 10.1128/JVI.75.19.9201-9209.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function.

Authors:  C Tabernero; A S Zolotukhin; A Valentin; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

2.  Chimeric papillomavirus-like particles.

Authors:  M Müller; J Zhou; T D Reed; C Rittmüller; A Burger; J Gabelsberger; J Braspenning; L Gissmann
Journal:  Virology       Date:  1997-07-21       Impact factor: 3.616

Review 3.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

4.  A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.

Authors:  S Zolotukhin; M Potter; W W Hauswirth; J Guy; N Muzyczka
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells.

Authors:  C H Kim; Y Oh; T H Lee
Journal:  Gene       Date:  1997-10-15       Impact factor: 3.688

6.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA.

Authors:  K Grassmann; B Rapp; H Maschek; K U Petry; T Iftner
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.

Authors:  F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

9.  Protection against papillomavirus with a polynucleotide vaccine.

Authors:  J J Donnelly; D Martinez; K U Jansen; R W Ellis; D L Montgomery; M A Liu
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen).

Authors:  P Sundaram; W Xiao; J L Brandsma
Journal:  Nucleic Acids Res       Date:  1996-04-01       Impact factor: 16.971

View more
  71 in total

1.  Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells.

Authors:  Daniel Oberg; Brian Collier; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Authors:  Luise Florin; Katrin A Becker; Cornelia Sapp; Carsten Lambert; Hüseyin Sirma; Martin Müller; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo.

Authors:  Kong-Nan Zhao; WenYi Gu; Ning Xia Fang; Nicholas A Saunders; Ian H Frazer
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

5.  A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Authors:  Nadine Kämper; Patricia M Day; Thorsten Nowak; Hans-Christoph Selinka; Luise Florin; Jan Bolscher; Lydia Hilbig; John T Schiller; Martin Sapp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells.

Authors:  Seiichiro Mori; Saori Ozaki; Toshiharu Yasugi; Hiroyuki Yoshikawa; Yuji Taketani; Tadahito Kanda
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

7.  The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.

Authors:  Marc A Schneider; Konstanze D Scheffer; Timo Bund; Fatima Boukhallouk; Carsten Lambert; Cristina Cotarelo; Gert O Pflugfelder; Luise Florin; Gilles A Spoden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Authors:  Benjamin D Grant; Chelsey A Smith; Philip E Castle; Michael E Scheurer; Rebecca Richards-Kortum
Journal:  Vaccine       Date:  2016-09-22       Impact factor: 3.641

10.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.